Latest Research – Stem Cell Research Market to 2017

In Regenerative Medicine by Simon Crompton-ReidLeave a Comment

330px-Stem_cell_treatments.svg

 

 

 

 

GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Research Market to 2017 – Strong Pipeline, High Unmet Needs in Chronic Diseases and Favourable Government Policies to Boost Stem Cell R&D".

The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.

The stem cell therapies market has tremendous market potential in future. GBI Research analysis suggests that high unmet need in some of the major chronic diseases and a strong stem cell pipeline in those indications will drive the market growth for stem cell therapies in future. The immense market potential will also result in boost to further research in the area. In addition, increasingly sup prove regulatory environment and more investments into stem cell R&D will boost the market prospects in future.

The key reason for the high potential in the stem cell research market is due the ability of stem cell therapies to treat the cause of the disease instead of just managing the symptoms, which is what the current conventional therapies are doing. Looking from a commercial perspective, this deficit of curative treatments leads to loss of growth opportunities for the pharmaceutical industries. This is where, stem cell research provides alternative to the conventional pharmaceutical and biotech research where they provide curative treatment instead of symptomatic, thereby serving the unmet need.

Increasing Entry of the Pharmaceutical Companies would Drive the Stem Cell Research and Development

Over the years, there has been a spur in investments from pharmaceutical companies in stem cell research wherein they have collaborated with the stem cell research companies to provide research support. Major pharmaceutical companies have planned and aligned their objectives in the stem cells space for the next five years.

Pharmaceutical companies are exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules. Many top pharmaceutical companies have already begun work along with leading academic and stem cell research companies. These companies ensure that the research projects meet ethical standards. At present, top pharmaceutical companies are investing in stem cell research and some mid-size pharmaceutical companies have shown interest to invest in the future.

GlaxoSmithKline, Pfizer, Novartis, Novo Nordisk, Teva Pharmaceuticals and Roche are few of the top companies that are actively involved in stem cell research. The Hybrid model of stem cell research and development is in the growth stage. In most partnerships, the pharmaceutical companies fund the research and benefit from the outcome of the research work. Stem cell research based companies receive an upfront fee, licensing fee and potential milestone payments. At present, this is the revenue generating model for most stem cell research based companies.

High Unmet Needs and Promising Phase III Trials Boosts Stem Cell Research and Development

The current lack of curative treatments for chronic diseases is expected to be met by Stem cell therapies. In spite of advancements in medical technologies, there are very few treatment options available in the market to cure certain cardiovascular disorders, cancers, autoimmune and inflammatory disorders, spinal cord injury and others. Also, most of these therapies treat the symptoms without curing the disease. Stem cell therapies will help to fill this gap with the use of novel therapeutic approaches that have the ability to cure the disease. Promising pipeline drugs in Phase III has increased the hopes of commercialization of stem cell therapies.

The total number of stem cell clinical trials has increased tremendously over the last few years. With more than 60 ongoing Phase III trials, the market is keenly awaiting the launch of these therapies within the next four to six years. The launch of the drugs in the stem cell research is going to drive the market as a majority of the therapies belong to oncology followed by cardiovascular and immunology related disorders. The Preclinical research and Phase I trials have also increased at a phenomenal rate. This increase demonstrates the emerging interests in stem cell research across the globe.

To order this report, or to find out more visit GBI Research.

Leave a Comment

Current ye@r *